Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
5.
Surg Radiol Anat ; 44(1): 49-53, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1626305

ABSTRACT

PURPOSE: The purpose of the present study was to assess the online search behavior for the keyword "anatomy" worldwide and to compare the pre-pandemic and during COVID-19 pandemic scenario for the same. METHODS: Google trends tool was used for the assessment of the search behavior for the term "anatomy". The data, i.e. relative search volume (RSV) were downloaded for this term using the all categories, web search and only YouTube settings during a period from 1.1.2019 to 3.31.2021 from www.trends.google.com . The geographic trends for this search query were plotted across the world. RESULTS: Seasonal peaks were observed for the search term "anatomy" during the first 3 months of the year and in months of September, October and November in 2019. Similar seasonal peaks were observed for the year 2020 except that there was sudden decrease in RSV for term "anatomy" in the month of March. Though trend for the rest of the year was same, but there was general lower RSV in 2020. The country with highest search hit was United States followed by Canada, Ireland, Australia and Philippines. CONCLUSION: The search trend for pre-pandemic and pandemic period was similar with overall lower RSV during 2020, where it noticeably decreased during the initial phase of lockdown, i.e. in the month of March. As the whole world is still in the COVID-19 pandemic era, the future studies may report the google trends once the pandemic is over and may compare the post-pandemic trend for the same.


Subject(s)
COVID-19 , Communicable Disease Control , Humans , Pandemics , SARS-CoV-2 , Search Engine , United States
6.
J Investig Med ; 70(1): 55-60, 2022 01.
Article in English | MEDLINE | ID: covidwho-1438106

ABSTRACT

Tocilizumab is an interleukin receptor inhibitor that has been used in patients with COVID-19 pneumonia. There are recent randomized controlled trials (RCTs) that evaluated the efficacy and safety of tocilizumab in hospitalized patients with COVID-19 pneumonia. We performed a systematic review and meta-analysis of RCTs that evaluated the effectiveness of tocilizumab in hospitalized patients with COVID-19 not requiring mechanical ventilation. RCTs comparing tocilizumab with the standard of care treatment in hospitalized patients with COVID-19 pneumonia not requiring mechanical ventilation at the time of administration were included for analysis. The primary outcome was a composite of mechanical ventilation or 28-day mortality and the secondary outcomes were 28-day mortality and major adverse events. A total of 6 RCTs were included for the analysis. Tocilizumab was associated with a statistically significant reduction in the primary composite outcome of mechanical ventilation or 28-day mortality (risk ratio (RR): 0.83 (95% CI: 0.74 to 0.92, I2=0, tau2=0). Treatment with tocilizumab did not show a statistically significant reduction in 28-day mortality (RR: 0.90 (95% CI: 0.76 to 1.07), I2=0, tau2=0) and rate of serious adverse events (RR: 0.82 (95% CI: 0.62 to 1.10), I2=0, tau2=0). Tocilizumab was associated with a decrease in the incidence of primary outcome, that is, mechanical ventilation or death at 28 days in hospitalized patients with COVID-19 pneumonia.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19 Drug Treatment , COVID-19/diagnosis , Female , Hospitalization , Humans , Male , Randomized Controlled Trials as Topic , SARS-CoV-2 , Treatment Outcome
7.
Cardiovasc Diagn Ther ; 11(3): 939-953, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1296311

ABSTRACT

Coronavirus disease (COVID-19), first identified in Wuhan, China, in December 2019, is now a pandemic, having already spread to 188 countries, with more than 28,280,000 infections worldwide. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the responsible infectious agent, and similar to other human coronaviruses, uses membrane-bound angiotensin-converting enzyme 2 (membrane-bound ACE2) for entry into the host cells. COVID-19 has important cardiovascular implications, especially for patients with pre-existing cardiovascular co-morbidities, potentially mediated through several mechanisms, including direct myocardial injury, worsening of those pre-existing cardiovascular co-morbidities, and adverse cardiovascular effects of potential therapies for COVID-19. The disease is causing a significant burden on health systems worldwide. Elective surgeries and procedures were postponed for a considerable period of time, and many patients with known cardiovascular disease (CVD) risk factors presented late to hospitals, for fear of contracting COVID-19, with serious adverse consequences. Significant negative impact on a population level is highlighted by prolonged isolation, decreased exercise and physical activity, and higher levels of depression and anxiety, all predisposing to elevated cardiovascular risk. This article provides a timely overview of COVID-19 and its impact on the cardiovascular system, focusing on the pathogenesis, potential adverse cardiovascular events, the potential treatment options, protection for health care providers and patients, and what the cardiovascular community could do to mitigate the impact of COVID-19.

8.
Surg Radiol Anat ; 43(4): 515-521, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1168968

ABSTRACT

PURPOSE: During this forced down-time of COVID-19 pandemic, shift to virtual anatomy education is the solitary solution to support the learning of students. The purpose of this study was to understand the visible and invisible potential challenges being faced by the 1st year medical and dental students while attending digital anatomy classes. METHODS: The present study was conducted on 81st year medical and dental students who were admitted to their respective college in August 2019 and were willing to participate in the study. A multiple choice close-ended questionnaire regarding their opinion on virtual classes was designed and feedback was taken from the students. RESULTS: Majority (65%) of the students agreed that they missed their traditional anatomy learning i.e., dissection courses, face to face lectures and interaction with mentors. The students strongly felt the lack of confidence and difficulty in the topics completed without dissections, models, microscopic slides and other modalities. 83% felt lack of proper gadgets, high-band width and strong internet connections, a potential barrier in their digital learning. Lack of self-motivation was felt by 69% students. CONCLUSIONS: The current situation of anatomy education is not intentional, and is not the long term silver bullet solution for a visual subject like anatomy. Though learners face a lot of challenges, however, a shift to online must be supported at this time of health crisis. As the digital learning may go for indefinite period, the feedback of students may be helpful for relevant and timely modifications in digital anatomy education.


Subject(s)
Anatomy/education , COVID-19/prevention & control , Education, Dental/methods , Education, Distance/methods , Education, Medical, Undergraduate/methods , COVID-19/epidemiology , COVID-19/transmission , Communicable Disease Control/standards , Curriculum/statistics & numerical data , Dissection/education , Education, Dental/standards , Education, Dental/statistics & numerical data , Education, Distance/standards , Education, Distance/statistics & numerical data , Education, Medical, Undergraduate/standards , Education, Medical, Undergraduate/statistics & numerical data , Humans , India/epidemiology , Learning , Pandemics/prevention & control , Personal Satisfaction , Students, Dental/psychology , Students, Dental/statistics & numerical data , Students, Medical/psychology , Students, Medical/statistics & numerical data , Surveys and Questionnaires/statistics & numerical data
9.
Am J Cardiol ; 141: 140-146, 2021 02 15.
Article in English | MEDLINE | ID: covidwho-1059826

ABSTRACT

Current evidence is limited to small studies describing the association between cardiac injury and outcomes in patients with coronavirus disease 2019 (COVID-19). To address this, we performed a comprehensive meta-analysis of studies in COVID-19 patients to evaluate the association between cardiac injury and all-cause mortality, intensive care unit (ICU) admission, mechanical ventilation, acute respiratory distress syndrome, acute kidney injury and coagulopathy. Further, studies comparing cardiac biomarker levels in survivors versus nonsurvivors were included. A total of 14 studies (3,175 patients) were utilized for the final analysis. Cardiac injury in patients with COVID-19 was associated with higher risk of mortality (risk ratio [RR]:7.79; 95% confidence interval [CI]: 4.69 to 13.01; I2=58%), ICU admission (RR: 4.06; 95% CI: 1.50 to 10.97; I2 = 61%), mechanical ventilation (RR: 5.53; 95% CI: 3.09 to 9.91; I2 = 0%), and developing coagulopathy (RR: 3.86; 95% CI:2.81 to 5.32; I2 = 0%). However, cardiac injury was not associated with increased risk of acute respiratory distress syndrome (RR:3.22; 95% CI:0.72 to 14.47; I2 = 73%) or acute kidney injury (RR: 11.52, 95% CI:0.03 to 4,159.80; I2 = 0%). The levels of hs-cTnI (MD:34.54 pg/ml;95% CI: 24.67 to 44.40 pg/ml; I2 = 88%), myoglobin (MD:186.81 ng/ml; 95% CI: 121.52 to 252.10 ng/ml; I2 = 88%), NT-pro BNP (MD:1183.55 pg/ml; 95% CI: 520.19 to 1846.91 pg/ml: I2 = 96%) and CK-MB (MD:2.49 ng/ml;95% CI: 1.86 to 3.12 ng/ml; I2 = 90%) were significantly elevated in nonsurvivors compared with survivors with COVID-19 infection. The results of this meta-analysis suggest that cardiac injury is associated with higher mortality, ICU admission, mechanical ventilation and coagulopathy in patients with COVID-19.


Subject(s)
COVID-19/epidemiology , Heart Diseases/epidemiology , Pandemics , Comorbidity , Global Health , Humans , SARS-CoV-2 , Survival Rate/trends
10.
Int J Infect Dis ; 103: 579-589, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1039386

ABSTRACT

India imposed one of the world's strictest population-wide lockdowns on March 25, 2020 for COVID-19. We estimated epidemiological parameters, evaluated the effect of control measures on the epidemic in India, and explored strategies to exit lockdown. We obtained patient-level data to estimate the delay from onset to confirmation and the asymptomatic proportion. We estimated the basic and time-varying reproduction number (R0 and Rt) after adjusting for imported cases and delay to confirmation using incidence data from March 4 to April 25, 2020. Using a SEIR-QDPA model, we simulated lockdown relaxation scenarios and increased testing to evaluate lockdown exit strategies. R0 for India was estimated to be 2·08, and the Rt decreased from 1·67 on March 30 to 1·16 on April 22. We observed that the delay from the date of lockdown relaxation to the start of the second wave increases as lockdown is extended farther after the first wave peak-this delay is longer if lockdown is relaxed gradually. Aggressive measures such as lockdowns may be inherently enough to suppress an outbreak; however, other measures need to be scaled up as lockdowns are relaxed. Lower levels of social distancing when coupled with a testing ramp-up could achieve similar outbreak control as an aggressive social distancing regime where testing was not increased.


Subject(s)
COVID-19/transmission , SARS-CoV-2 , COVID-19/epidemiology , COVID-19/prevention & control , Epidemics , Humans , India/epidemiology
12.
Trends Cardiovasc Med ; 31(3): 135-140, 2021 04.
Article in English | MEDLINE | ID: covidwho-989276

ABSTRACT

As the prevalence of asymptomatic COVID-19 continues to increase, there is an increasing possibility that patients with COVID-19 may presen with ST-segment elevation myocardial infarction (STEMI). With social distancing and restricted access to preventive healthcare and emergency services, the management of acute cardiac emergencies such as myocardial infarction has suffered collateral damage. Thus far, global trends suggest a decrease in STEMI activations with possible worse outcomes due to delayed presentation and management. In this review, we discuss the challenges to STEMI management in the COVID-19 era and provide potential solutions for adherence to evidence-based therapies as the pandemic progresses into the year 2021.


Subject(s)
COVID-19/complications , Infection Control/organization & administration , ST Elevation Myocardial Infarction/therapy , COVID-19/epidemiology , COVID-19/prevention & control , Humans , Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction/diagnosis , ST Elevation Myocardial Infarction/etiology
13.
Heart Lung ; 50(1): 9-12, 2021.
Article in English | MEDLINE | ID: covidwho-778906

ABSTRACT

AIM: To determine if D-dimers are elevated in individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who have adverse clinical outcomes including all-cause mortality, intensive care unit (ICU) admission or acute respiratory distress syndrome (ARDS). METHODS: We conducted a systematic review and meta-analysis of the published literature in PubMed, Embase and Cochrane databases through April 9, 2020 for studies evaluating D-dimer levels in SARS-COV-2 infected patients with and without a composite clinical endpoint, defined as the presence of all-cause of mortality, Intensive care unit (ICU) admission or acute respiratory distress syndrome (ARDS). A total of six studies were included in the meta-analysis. RESULTS: D-dimers were significantly increased in patients with the composite clinical end point than in those without (SMD, 1.67 ug/ml (95% CI, 0.72-2.62 ug/ml). The SMD of the studies (Tang et al, Zhou et al, Chen et al), which used only mortality as an outcome measure was 2.5 ug/mL (95% CI, 0.62-4.41 ug/ml). CONCLUSION: We conclude that SARS-CoV-2 infected patients with elevated D-dimers have worse clinical outcomes (all-cause mortality, ICU admission or ARDS) and thus measurement of D-dimers can guide in clinical decision making.


Subject(s)
COVID-19 , Fibrin Fibrinogen Degradation Products , Respiratory Distress Syndrome , COVID-19/blood , COVID-19/mortality , Clinical Decision-Making , Fibrin Fibrinogen Degradation Products/analysis , Humans , Inpatients , Intensive Care Units , Prognosis , SARS-CoV-2
15.
J Med Syst ; 44(9): 156, 2020 Aug 01.
Article in English | MEDLINE | ID: covidwho-691720

ABSTRACT

The term machine learning refers to a collection of tools used for identifying patterns in data. As opposed to traditional methods of pattern identification, machine learning tools relies on artificial intelligence to map out patters from large amounts of data, can self-improve as and when new data becomes available and is quicker in accomplishing these tasks. This review describes various techniques of machine learning that have been used in the past in the prediction, detection and management of infectious diseases, and how these tools are being brought into the battle against COVID-19. In addition, we also discuss their applications in various stages of the pandemic, the advantages, disadvantages and possible pit falls.


Subject(s)
Algorithms , Artificial Intelligence , Betacoronavirus , Coronavirus Infections , Pandemics , Pneumonia, Viral , COVID-19 , Humans , Machine Learning , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL